<DOC>
	<DOCNO>NCT02845414</DOCNO>
	<brief_summary>This single center , phase I dose escalation study design determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) deimmunized CD133KDEL ( dCD133KDEL ) , ligand-directed , deimmunized pseudomonas toxin CD133 , patient advance , previously treat , refractory solid tumor .</brief_summary>
	<brief_title>Study CD133KDEL Toxin Treatment Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Pathologically cytologically confirm , metastatic unresectable solid tumor malignancy . 2 . Measurable evaluable disease per RECIST 1.1 criterion ( Appendix II ) , modify RECIST criterion mesothelioma ( Appendix II ) . 3 . At least 1 prior line systemic therapy consider standard malignancy , standard therapy exist . Prior systemic chemotherapy , immunotherapy , biological therapy , radiation therapy and/or surgery allow first dose dCD133KDEL follow restriction : At least 14 day since systemic therapy . At least 28 day since experimental therapy . At least 14 day since radiation therapy . At least 28 day since major surgery , define surgery involve risk life patient , specifically , operation upon organ within cranium , chest , abdomen , pelvic cavity . 4 . Recovered acute toxic effect ( ≤ grade 1 , CTCAE v4.0 ) previous cancer treatment prior study registration . 5 . ECOG performance status 0 1 ( Appendix III ) . 6 . Adequate organ function within 14 day study registration , define follow System Parameter Laboratory Value Hematologic Absolute neutrophil count ( ANC ) ≥1.5 x 10^9 /L Hemoglobin* 9 g/dL Platelets* ≥100 x 10^9 /L Hepatic Total bilirubin &lt; 2 x ULN^ ALT &lt; 2 x ULN^ Renal Serum creatinine &lt; 1.5 mg/dL OR estimate GFR &gt; 50 modify CockcroftGault ( * Patient may transfusion within 7 day ^ Upper limit institutional normal . ) 7 . Albumin ≥ 3.0 gm/dL within 14 day study registration . 8 . Adequate cardiac function , define ejection fraction ≥40 % transthoracic echocardiogram do within 14 day study registration . 9 . QT/QTc interval ≤ 450 millisecond within 14 day study registration . If screening EKG demonstrate QT/QTc interval &gt; 450 millisecond , second screening EKG do within 7 day document QT prolongation persistent . The patient eligible second screening EKG show QT/QTc interval ≤ 450 millisecond require additional EKGs study period outline section 6.1.2 . 10 . Adequate pulmonary function , define rest oxygen saturation ≥ 90 % room air and/or pulmonary function test ( PFT ) show correct DLCO &gt; 50 % FEV1 ≥ 2 liter ≥ 60 % predict . PFT test require within 28 day study registration patient symptomatic prior know impairment present . 11 . Females childbearing potential male partner childbearing potential must agree use 2 effective contraception method , one must barrier method , study ≥12 week last dose dCD133KDEL . Effective method include intrauterine device ( IUD ) , DepoProvera injection implant , Evra patch , NuvaRing , oral contraception , diaphragm/spermicide condom . 12 . Ability understand provide voluntary write consent . 1 . Known active CNS metastases neurological symptom possibly relate CNS metastasis , spinal cord compression , evidence leptomeningeal disease . Patients history brain metastasis undergone whole brain radiation gamma knife treatment ≥ 28 day prior registration , whose metastasis document stable resolved time screen brain MRI ( head CT contrast intolerant MRI ) , require ≥10 mg prednisone equivalent symptom management relate brain metastasis , eligible . 2 . Known uncontrolled cardiac arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality within 28 day registration . 3 . Uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement . 4 . History one cardiovascular condition within 12 week study registration cardiac angioplasty stenting myocardial infarction unstable angina coronary artery bypass graft surgery symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA , Appendix IV ) transient ischemic attack and/or cerebrovascular accident 5 . History another malignancy nonmelanoma skin cancer treat carcinoma situ , unless document disease free least 3 year . 6 . History allergic reaction sensitivity compound similar chemical biological composition dCD133KDEL , component dCD133KDEL ( i.e . Polysorbate 80 ) . 7 . Pregnant breastfeed woman , woman intend become pregnant . Females child bear potential must negative serum pregnancy test within 14 day study registration . 8 . Prior toxindirected therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>